Naproxen: a New Strategy to Reduce the Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs (Scientific Review)

N.K. Svyrydova

Abstract


Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for the treatment of pain and inflammation, including neurodystrophic, post-traumatic, demyelinating, oncology diseases, as well as diseases of the musculoskeletal system. NSAIDs are prescribed for both short-term and long-term use. Their prolonged use often leads to the side effects, mainly gastrointestinal, cardiovascular and renal. The therapeutic strategy for the effective application of NSAIDs, development and use of new biomarkers to identify patients most at risk for gastrotoxicity and cardiovascular complications will increase the efficiency of the treatment for various pathologies. Naproxen sodium has the desired spectrum of therapeutic activity (ability to inhibit the inflammatory reaction, expressed analgesic activity) in combination with the highest profile of cardiovascular safety among the NSAIDs. This combined action makes it promising in the existing alternative therapy of various inflammations and pain.


Keywords


non-steroidal anti-inflammatory drugs; cardiovascular risk; gastrotoxicity; pain; reducing the risk of complications; naproxen

References


Ghosh R., Alajbegovic A., Gomes A. NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species // Oxid Med. Cell. Longev. 2015: 536-962.

Crofford L.J. Use of NSAIDs in treating patients with arthritis // Arthritis Research & Therapy. 2013; 15(supplement 3, article S2); doi: 10.1186/ar4174.

Cha Y.I., DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX‑2 // Annual Review of Medicine. 2007; 58: 239-252.

Cuzick J., Otto F., Baron J.A., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement // The Lancet Oncology. 2009; 10(5): 501-507.

Liggett J.L., Zhang X., Eling T.E., Baek S.J. Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets // Cancer Letters. 2014; 346(2): 217-224.

Lanza F.L., Chan F.K.L., Quigley E.M.M. Guidelines for prevention of NSAID-related ulcer complications // The American Journal of Gastroenterology. 2009; 104(3): 728-738.

Lanas Á., Carrera-Lasfuentes P., Arguedas Y., et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulant // Clinical Gastroenterology and Hepatology. 2014; doi: 10.1016

Lapi F., Azoulay L., Yin H., Nessim S.J., Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study // British Medical Journal. 2013; 346(7890).

Taubert K.A. Cardiology patient pages: can patients with cardiovascular disease take nonsteroidalantiinflammatory drugs? // Circulation. 2008; 117(17): e322-e324.

Soyun M., Hwang J.E.G., Cui Z., Gomes A.V. Non-Steroidal Anti-Inflammatory Drugs and Increased Risk of Sudden Cardiac Death. — ​Hauppauge, NY, USA: Nova Science Publisher, 2013.

Anonymous. 2011. Etoricoxib. Wikipedia: the free encyclopedia. Available: http: //en.wikipedia.org/wiki/Etoricoxib. Accessed 6 August 2011.

Barozzi N., Tett S.E. What happened to the prescribing of other COX‑2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? // Pharmacoepidemiol. Drug Saf. 2007; 16: 1184-1191.

Rubin B.R., Burton R., Navarra S., Antigua J., Londoño J. et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial // Arthritis Rheum. 2004; 50: 598-606.

McGettigan P., Henry D. Cardiovascular risk and inhibition of cylcooxygenase: a systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase‑2 // JAMA. 2006; 296: 1633-1644.

Fosbol E.L., Folke F., Gislason G.H., Jacobsen S., Rasamussen J.N. et al. Cause-specific cardiovascular risk associated with non-steroidal anti-inflammatory drugs among healthy individuals // Circ. Cardiovasc. Qual. Outcomes. 2010; 3: 395-405.

McGettigan P., Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies // PLoS Med. 2011 Sep; 8(9): e1001098.

DuBois R.N., Abramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease // The FASEB Journal. 1998; 12(12): 1063-1073.

Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2 // The Journal of Biological Chemistry. 1996; 271(52): 33157-33160.

Maślińska D., Woźniak R., Kaliszek A., Modelska I. Expression of cyclooxygenase‑2 in astrocytes of human bRAin after global ischemia // Folia Neuropathologica. 1999; 37(2): 75-79.

Nantel F., Meadows E., Denis D., Connolly B., Metters K.M., Giaid A. Immunolocalization of cyclooxygenase‑2 in the macula densa of human elderly // FEBS Letters. 1999; 457(3): 475-477.

Zidar N., Odar K., Glavac D., Jerse M., Zupanc T., Stajer D. Cyclooxygenase in normal human tissues — ​is COX‑1 really a constitutive isoform, and COX‑2 an inducible isoform? // Journal of Cellular and Molecular Medicine. 2009; 13(9): 3753-3763.

Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxibvsnonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial // The Journal of the American Medical Association. 2000; 284(10): 1247-1255.

Rodríguez L.A.G., Tolosa L.B. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population // Gastroenterology. 2007; 132(2): 498-506.

Goldstein J.L., Silverstein F.E., Agrawal N.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX‑2 inhibitor // The American Journal of Gastroenterology. 2000; 95(7): 1681-1690.

Helin-Salmivaara A., Virtanen A., Vesalainen R., et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland // European Heart Journal. 2006; 27(14): 1657-1663.

Amer M., Bead V.R., Bathon J., Blumenthal R.S., Edwards D.N. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale // Cardiology in Review. 2010; 18(4): 204-212.

Rostom A., Moayyedi P., Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks // Alimentary Pharmacology & Therapeutics. 2009; 29(5): 481-496.

Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX‑2 inhibitors parecoxib and valdecoxib after cardiac surgery // The New England Journal of Medicine. 2005; 352(11): 1081-1091.

Antman E.M., Bennett J.S., Daugherty A., Furberg C., Ro­berts H., Taubert K.A. Use of nonsteroidalantiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association // Circulation. 2007; 115(12): 1634-1642.

Farkouh M.E., Greenberg B.P. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs // The American Journal of Cardiology. 2009; 103(9): 1227-1237.

Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX‑2 inhibitors // The Journal of the American Medical Association. 2001; 286(8): 954-959.

Bhala N., Emberson J., Merhi A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials // The Lancet. 2013; 382(9894): 769-779.

Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials // Lancet. 2013 Aug 31; 382(9894): 769-779.

Blackler R., Syer S., Bolla M., Ongini E., Wallace J. Gastrointestinal-Sparing Effects of Novel NSAIDs in Rats with Compromised Mucosal Defence // PLoS One. 2012; 7(4): e35196.

Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement // N. Engl. J. Med. 2009; 361: 594-604.

Lassen M.R., Gallus A., Raskob G.E., Pineo G., Chen D., Ramirez L.M. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement // N. Engl. J. Med. 2010; 363: 2487-2498.

Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // N. Engl. J. Med. 2011; 364: 806-817.

Granger C.B., Alexander J.H., McMurray J.J. et al. // Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011; 365: 981-992.

Agnelli G., Buller H.R., Cohen A., et al. // AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism // N. Engl. J. Med. 2013; 369: 799-808.

Agnelli G., Buller H.R., Cohen A. et al. // AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism // N. Engl. J. Med. 2013; 368: 699-708.

Falck-Ytter Y., Francis C.W., Johanson N.A. et al. // Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines // Chest. 2012; 141: e278S-e325S.

Moote C. Efficacy of nonsteroidal anti-inflammatory drugs in the management of postoperative pain // Drugs. 1992; 44(Suppl. 5): 14-29.

Shah A.A., Murray F.E., Fitzgerald D.J. The in vivo assessment of nimesulide cyclooxygenase‑2 selectivity // Rheumatology (Oxford). 1999; 38(Suppl. 1): 19-23.

Wang L., Zhang D., Raghavan N. et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies // Drug Metab. Dispos. 2010; 38: 448-458.

Zhang D., He K., Herbst J.J. et al. Characterization of efflux transporters involved in distribution and disposition of apixaban // Drug Metab. Dispos. 2013; 41: 827-835.

Tracy T.S., Marra C., Wrighton S.A., Gonzalez F.J., Korzekwa K.R. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation // Eur. J. Clin. Pharmacol. 1997; 52: 293-298.

Rodgers R.P., Levin J. A critical reappraisal of the bleeding time // Semin. Thromb. Hemost. 1990; 16: 1-20.

Bhala N., Emberson J., Merhi A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials // The Lancet. 2013; 382(9894): 769-779.

Mason R.P., Walter M.F., McNulty H.P., et al. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity // Journal of Cardiovascular Pharmacology. 2006; 47(supplement 1): S7-S14.

Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial // The New England Journal of Medicine. 2005; 352(11): 1092-1102.

Kohli P., Steg P.G., Cannon C.P., et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease // The American Journal of Medicine. 2014; 127(1): 53-60.

Helin-Salmivaara A., Virtanen A., Vesalainen R., et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland // European Heart Journal. 2006; 27(14): 1657-1663.

Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxyge­nase‑2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study // The Lancet. 2004; 363(9423): 1751-1756.

Farkouh M.E., Greenberg B.P. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs // The American Journal of Cardiology. 2009; 103(9): 1227-1237.

Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX‑2 inhibitors // The Journal of the American Medical Association. 2001; 286(8): 954-959.

McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies // PLoS Medicine. 2011; 8(9)

ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s disease anti-inflammatory prevention trial (ADAPT) PLoS Clinical Trials. 2006; 1(7, article e33)

Solomon S.D., McMurray J.J.V., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention // The New England Journal of Medicine. 2005; 352(11): 1071-1080.

McGettigan P., Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies // PLoS Med. 2011 Sep; 8(9): e1001098.

Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R. et al. Do selective cyclo-oxygenase‑2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials // BMJ. 2006; 332: 1302-1308.

Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis // BMJ. 2011; 342: c7086.

García Rodríguez L.A., González-Pérez A., Bueno H., Hwa J. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies // PLoS ONE. 2011; 6: e16780.

Lúcio M., Ferreira H., Lima J.L., Reis S. Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity // Med. Chem. 2006; 2: 447-456.

Henry D., Lim L.L., García Rodríguez L.A., Perez Gutthann S., Carson J.L., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis // BMJ. 1996; 312: 1563-1566.

Rubin B.R., Burton R., Navarra S., Antigua J., Londoño J., et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial // Arthritis Rheum. 2004; 50: 598-606.

Anonymous. 2011. Indomethacin: drug information provided by Lexi-Comp. The Merck Manual for Health Care Professionals. Available: http: // www.merckmanuals. com/professional/lexicomp /indomethacin.html. Accessed 6 August 2011.

Hawkey C., Kahan A., Steinbruck K., Alegre C., Baumelou E. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients // Br. J. Rheumatol. 1998; 37: 937-945.

Undas A., Brummel-Ziedins K.E., Mann K.G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions // Blood. 2007; 109(6): 2285-2292. doi: 10.1182/blood‑2006-01-010645.

Vesterqvist O., Green K. Effects of naproxen on the in vivo synthesis of thromboxane and prostacyclin in man // European Journal of Clinical Pharmacology. 1989; 37(6): 563-565.

US Food and Drug Administration. Thrombotic cardiovascular events associated with NSAID use: regulatory history and results of literature search (RCTs). Proceedings of the Joint Meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee; February 2014.

Kim I.-Y., Park S.-​Y., Kang Y., Thapa D., Choi H.G., Kim J.-A. Role of nonsteroidal anti-inflammatory drug-activated gene‑1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status // Archives of Pharmacal Research. 2011; 34(2): 323-330.

Ray W.A., Varas-Lorenzo C., Chung C.P., et al. Cardiovascular risks of nonsteroidalantiinflammatory drugs in patients after hospitalization for serious coronary heart disease // Circulation: Cardiovascular Quality and Outcomes. 2009; 2(3): 155-163.

Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis // The New England Journal of Medicine. 2000; 343(21): 1520-1528.

Mason J., Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions // Eur. Heart J. 2015 Feb 21; 36(8): 482-489.

Kitas G.D., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives // Ann. Rheum. Dis. 2011; 70: 8-14.

Wallberg-Jonsson S., Johansson H., Ohman M.L., Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset // J. Rheumatol. 1999; 26: 2562-2571.

Frost C., Shenker A., Gandhi M. et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban // Br. J. Clin. Pharmacol. 2014 Oct; 78(4): 877-885.

Barrett Y.C., Wang J., Song Y., Pursley J., Wastall P., Wright R., La Creta F., Frost C. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects // Thromb. Haemost. 2012; 107: 916-924.

Frost C., Wang J., Nepal S., Schuster A., Barrett Y.C., Mosqueda-Garcia R., Reeves R.A., La Creta F. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects // Br. J. Clin. Pharmacol. 2013; 75: 476-487.

Shah A.A., Murray F.E., Fitzgerald D.J. The in vivo assessment of nimesulide cyclooxygenase‑2 selectivity // Rheumatology (Oxford) 1999; 38(Suppl. 1): 19-23.

Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides // Arthritis Rheum. 2013; 65: 1-11.

Hawkey C., Hawkey G., Everitt S. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs // Br. J. Clin. Pharmacol. 2006 Jun; 61(6): 730-737.

Kurth T., Glynn R.J., Walker A.M., Chan K.A., Buring J.E., Hennekens C.H., Gaziano J.M. Inhibition of clinical benefits of aspirin on first myocardial infarction by non steroidalanti inflammatory drugs // Circulation. 2003; 108: 1191-5.

Patel T.N., Goldberg K.C. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction // Arch. Intern. Med. 2004; 164: 852-6.

Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., Di Gregorio P., Merciaro G., Patrono C., Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects // Circulation. 2004; 109: 1468-71.




DOI: https://doi.org/10.22141/2224-0713.5.83.2016.78478

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru